Oligometastatic non-small-cell lung cancer: current treatment strategies.

about

Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy.Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer.

P2860

Q47411144-DBA8D74D-1EC6-44A2-92A4-90BBC3329070 Q49365766-59DA761D-7ED9-4C41-8445-1236057E63B6

P2860

Oligometastatic non-small-cell lung cancer: current treatment strategies.

Item

http://www.wikidata.org/entity/Q37643566

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@en

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@nl

type

Item

label

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@en

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@nl

prefLabel

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@en

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@nl

P1476

Oligometastatic non-small-cell lung cancer: current treatment strategies.

@en

P2093

Patrick J Richard

http://www.w3.org/2001/XMLSchema#string

Ramesh Rengan

http://www.w3.org/2001/XMLSchema#string

P2860

Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Cancer statistics, 2015

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.

Stereotactic body radiation therapy for inoperable early stage lung cancer.

P304

129-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/LCTT.S101639

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28210169

http://www.w3.org/2001/XMLSchema#string

P932

5310708

http://www.w3.org/2001/XMLSchema#string

Oligometastatic non-small-cell lung cancer: current treatment strategies.

about

P2860

P2860

Oligometastatic non-small-cell lung cancer: current treatment strategies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932